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Ureaplasma urealyticum is the microorganism most frequent-
ly isolated from the amniotic fluid of women in preterm la-
bor. The relationship between intra-amniotic U. urealyticum in
healthy second-trimester pregnant women and subsequentpreg-
nancy outcome was investigated. Transabdominal amnioticfluid
obtained from 254 asymptomatic women at 15–17 weeks’ ges-
tation were tested by polymerase chain reaction (PCR). U. urea-
lyticum was identified in 29 subjects (11.4%). A subsequent
preterm labor occurred in 17 U. urealyticum–positive women
(58.6%), compared with 10 (4.4%) U. urealyticum–negative
women ( ). Preterm birth was documented in 7 (24.1%)P ! .0001
U. urealyticum–positive women compared with only 1 U. urea-
lyticum–negative woman (0.4%) ( ). U. urealyticum–P ! .0001
positive women also had a higher prevalence of preterm labor
in a prior pregnancy (20.7%) than did the negative women
(2.7%; ). PCR testing of second-trimester amnioticPp .0008
fluid for U. urealyticum can identify women at risk for subse-
quent preterm labor and delivery.
Ureaplasma urealyticum frequently colonizes the lower geni-
tal tract of pregnant women, without apparent adverse con-
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sequences [1]. In a small subpopulation of women, this mi-
croorganism ascends and colonizes the endometrium, either
before or after conception [2]. The difficulty resides in iden-
tifying the group at risk for ascending colonization. Passage of
U. urealyticum into the amniotic cavity appears to be an im-
portant step for prognosis of the pregnancy. Colonization of
the amniotic fluid has been documented as a major risk factor,
but usually the diagnosis is made too late for successful inter-
vention [3]. To minimize a possible adverse influence of U.
urealyticum in pregnancy outcome, a protocol to successfully
identify this microorganism early in the pregnancy would be
beneficial.
U. urealyticum is the microorganism most frequently cul-
tured by use of standard culture techniques from amniotic
fluids of women in preterm labor (PTL) with intact membranes
[4] or with preterm premature rupture of membranes (P-
PROM) [5]. Whether U. urealyticum intra-amniotic coloni-
zation in asymptomatic women during the second trimester is
also a risk factor for subsequent adverse pregnancy outcome
has been examined in only a few studies. U. urealyticum cul-
ture–positive amniotic fluids have been observed in a small
percentage of healthy asymptomatic women in the second tri-
mester of pregnancy [6–9]. In each of these studies, a positive
U. urealyticum culture was associated with an increased risk of
adverse pregnancy outcome in untreated patients, compared
with those who were culture-negative or who received antibiotic
treatment for this microorganism.
A recent study that used polymerase chain reaction (PCR)
to detect U. urealyticum in amniotic fluids from women with
P-PROM demonstrated that PCR was more sensitive than cul-
ture in detecting this microorganism in amniotic fluid and that
PCR-positive, culture-negative women were at high risk for
adverse pregnancy outcomes [10]. The objective of the present
investigation was to perform PCR testing on a large number
of second-trimester amniotic fluids from healthy asymptomatic
women to evaluate the prevalence of this mycoplasma and
whether its detection is associated with P-PROM or preterm
birth.
Subjects, materials, and methods. Amniotic fluid samples
were collected for analysis from 317 consecutive women who
underwent a transabdominal amniocentesis at weeks 15–17 of
pregnancy and were stored at 80C. Indications for amnio-
centesis were advanced maternal age, family history of chro-
mosomal abnormality, maternal request, or positive detection
on “triple test” for alpha fetoprotein, estriol, and beta human
chorionic gonadotropin. The same fetal ultrasound team per-
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Table 1. Relationship between Ureaplasma urealyticum in amni-
otic fluid and historical variables.
Variable
U. urealyticum status
PPositive Negative
Pregnancy, mean no. (range) 2.3 (1–5) 2.5 (1–9)
Birth, mean no. (range) 0.9 (0–4) 1.0 (0–4)
Age, mean years (range) 34.5 (25–42) 34.0 (19–42)
Previous preterm birth, no. (%) 6 (20.7) 6 (2.7) .0008
Table 2. Relationship between Ureaplasma urealyticum in amni-
otic fluid and pregnancy outcome.
Outcome variable
U. urealyticum status
P
Positive
(np 29)
Negative
(np 225)
PTL 17 (58.6) 10 (4.4) !.0001
Hospital stay for PTL 9 (31.0) 6 (2.7) !.0001
Birth
Before 37 weeks 7 (24.1) 1 (0.4) !.0001
Before 34 weeks 2 (6.9) 0 .01
P-PROM 6 (20.7) 1 (0.4) !.0001
Cesarean section 9 (31.0) 56 (24.9) NS
NOTE. Data are no. (%) of subjects. NS, not significant; P-PROM, preterm
premature rupture of membranes; PTL, preterm labor.
formed all procedures, using the identical method in every case.
Before the transabdominal amniocentesis, the skin was disin-
fected with 10% povidine iodine.
All women were white and of European background. Sub-
sequent pregnancy follow-up revealed that 63 (19.9%) of the
subjects had either an elective pregnancy termination or a com-
plicating pregnancy factor that placed them at risk for an ad-
verse outcome: placenta praevia, intrauterine growth restric-
tion, hypertension, cervical incompetence, or twin gestation.
The remaining 254 women had no known risk factor for ad-
verse pregnancy outcome.
U. urealyticum in amniotic fluid was detected by PCR using
a procedure detailed elsewhere [11], in which primer pairs to
a region of the urease gene are used, except that digoxigenin-
labeled dUTP was added to the reaction mixture. To ensure
specificity, the PCR amplicons were hybridized to a biotinylat-
ed oligonucleotide internal probe (5′-biotin-GCC CAC CAA
GAC TAT GAT GTT TAG-3′) and the complex detected in
duplicate by ELISA using streptavidin-coated wells of a micro-
titer plate and peroxidase-labeled anti-digoxigenin antibody
(Roche Diagnostics).
Stringent precautions used to prevent PCR product carryover
were the frequent changing of gloves and performance of the
processing, PCR, and hybridization in different rooms. Samples
were analyzed without knowledge of pregnancy outcomes.
Clinical pregnancy outcome data were obtained only after
the completion of all testing in a blinded fashion directly from
the patient and her private obstetrician. “PTL” was defined as
regular uterine contractions that indicated the use of a tocolytic
drug and bed rest at home after the exclusion of other etiologies
(i.e., bladder infection, cervical infection, or cervical incom-
petence). P-PROM was diagnosed by objective amniotic fluid
leakage (based on history, physical examination, and laboratory
testing) and/or diminution of amniotic fluid index before 37
weeks of pregnancy. In such cases, the condition of the patient
was managed by observation, in the absence of any infection
or fetal distress.
The relation between PCR outcome and other variables was
analyzed by Fisher’s exact test. was considered to beP ! .05
significant.
Results. During the 6-month study period, the same group
of physicians performed 317 amniocenteses. Of these, there was
1 pregnancy loss 2 weeks after, and 2 other patients developed
vaginal bleeding 24 and 48 h after the amniocentesis. Both
recovered after prolonged bed rest. Subsequent examination of
medical records revealed that 16 patients had an elective ter-
mination of the pregnancy, 2 had cervical incompetence, and
45 had a major complicating pregnancy factor. All were negative
for U. urealyticum, except for 2 sets of twin children.
U. urealyticum was detected by PCR in amniotic fluid from
29 (11.4%) of the remaining 254 asymptomatic women with
a singleton pregnancy. The relationship between U. urealyticum
detection and historical variables in these patients is shown in
table 1. There was no relationship between U. urealyticum col-
onization and the age or number of previous pregnancies or
births. However, women positive for U. urealyticum had a
higher occurrence of PTL in a prior pregnancy (20.7%) than
did the PCR-negative women (2.7%; ). Eight of thePp .0008
amniotic fluid samples were visibly discolored; none of these
were positive for U. urealyticum.
The relationship between U. urealyticum detection and out-
come of the pregnancy is shown in table 2. Intra-amniotic
carriage of U. urealyticum was highly associated with PTL, hos-
pitalization for PTL, P-PROM, and preterm birth before 37
weeks ( ). Delivery before 34 weeks’ gestation was ob-P ! .0001
served in 2 of the U. urealyticum–positive women and in none
of the U. urealyticum–negative women ( ).Pp .01
Discussion. In our study of 254 asymptomatic pregnant
patients in their early second trimester, 3% subsequently de-
veloped P-PROM and 10% underwent PTL, rates that were in
agreement with other studies [12]. Similarly, our incidence of
pregnancy loss (0.3%) and complication after midtrimester am-
niocentesis (0.9%) corresponded to traditional rates [13].
In the present study, detection of U. urealyticum by PCR in
second-trimester amniotic fluid of asymptomatic women was
highly correlated with subsequent PTL and preterm delivery.
The findings are similar to earlier investigations that examined
the impact on pregnancy of having a positive second-trimester
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amniotic fluid culture for U. urealyticum [6–9]. However, the
percentage of U. urealyticum–positive amniotic fluid samples
in our study exceeded that found in previous investigations
that used culture techniques. Possible explanations include the
enhanced sensitivity of PCR over culture for detection of this
microorganism in amniotic fluid [10] and/or population dif-
ferences in lower genital tract colonization or migration of U.
urealyticum to the upper genital tract. The extent of U. urealy-
ticum colonization is known to vary widely among populations
in different geographic areas [8]. U. urealyticum cultures were
not performed on amniotic fluids in the present study, so we
are unable to compare the sensitivity of our PCR with culture
for these samples.
Women in the present study who were positive for intra-
amniotic U. urealyticum also had a higher rate of PTL in pre-
vious pregnancies than did PCR-negative women. This obser-
vation is consistent with the possibility that U. urealyticum
might have been present in the endometrium as a persistent
colonizer before the current conception. This raises the inter-
esting possibility that it might be of value to sample the en-
dometrium for U. urealyticum prior to attempted conception
in women with a prior preterm birth. Detection and treatment
might improve subsequent pregnancy outcome. It has been
proposed elsewhere that preexisting infection of the uterine
cavity was a predisposing factor for subsequent adverse preg-
nancy outcomes [14].
It remains uncertain whether U. urealyticum directly induced
the observed pregnancy complications or whether this organ-
ism was merely a marker for another infection. It has been
suggested that the significance of U. urealyticum in amniotic
fluid is mainly its association with other microorganisms [15].
However, when standard culture techniques are used, U. urea-
lyticum is often the sole microorganism identified in the am-
niotic fluid of women in PTL and, furthermore, is associated
with elevated intra-amniotic levels of proinflammatory cyto-
kines [4, 6, 9, 10]. Studies that use more refined gene ampli-
fication analyses are necessary to definitively rule out the pres-
ence of additional microorganisms in U. urealyticum–positive
amniotic fluid samples and their relationship to adverse preg-
nancy outcome.
It should be noted that 76% of our patients with intra-amniotic
U. urealyticum gave birth at 37 weeks, whereas only 21% of
the U. urealyticum–positive patients developed P-PROM and
24% gave birth preterm. It would be of great interest to identify
markers predictive of adverse pregnancy outcomes in the U.
urealyticum–positive group. Perhaps a quantitative PCR or a
combination of PCR and culture to identify the extent of infec-
tion, would be of value. Evaluation of the inflammatory response
in amniotic fluid, determined by levels of proinflammatory cy-
tokines and matrix metalloproteinases, or the extent of a stress
response, measurable by heat shock protein determination, could
provide details of the fetal response to this microorganism. In
recent unpublished studies from our laboratory, possession of
allele 2 of the polymorphic interleukin-1 receptor antagonist gene
also appeared to increase the rate of adverse pregnancy outcome
after U. urealyticum infection. A detailed evaluation of a com-
bination of such markers may eventually lead to a method to
define the high-risk group in whom antibiotic treatment may
prove beneficial.
Nevertheless, the highly significant association between intra-
amniotic U. urealyticum and adverse pregnancy outcome
strongly suggests the potential value of PCR testing of pregnant
women in their second trimester for this organism. Routine
screening for U. urealyticum in amniotic fluid at the time of
midtrimester amniocentesis can identify the group of patients
who are infected with this microorganism. Further studies are
needed to assess whether all women with risk factors for pre-
maturity, or all women who undergo a second-trimester am-
niocentesis for other indications, might benefit from U. urea-
lyticum amniotic fluid testing. In addition, the possible use of
new antibiotic treatments such as azithromycin, which ex-
hibits an increased ease of transplacental passage, to improve
pregnancy outcome in U. urealyticum intra-amniotic infection
awaits further investigation.
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